Company History

  • April 2015

    Guizhou Taibang received a one-time special approval from the CFDA to purchase approximately 143 tonnes of source plasma and plasma paste from Xinjiang Deyuan Bioengineering Co., Ltd., for a total consideration of approximately RMB139 million (approximately US$22.6 million).
  • November 2014

    Shandong Taibang received the approval from the Hebei Provincial Health and Family Planning Commission to build two new plasma collection stations in Hebei Province.
  • October 2014

    Shandong Taibang received manufacturing approval certificate for Human Prothrombin Complex Concentrate ("PCC") from China Food and Drug Administration (“CFDA”).
  • Sept 2014

    China Biologic increased its equity interests in Guizhou Taibang to 76.23% through purchasing additional interest from a minority shareholder.
FirstPage | PreviousPage | NextPage | LastPage CurrentPageIndex:5 [1] [2] [3] [4] [5] [6] [7] [8] [9] ...
© 2018 China Biologic Products Holdings, Inc. All Rights Reserved.